The challenges of bringing new veterinary therapeutic
drugs to market are significant and require careful planning around research,
development, testing, manufacturing and regulatory processes. Understanding
the mechanisms of the interaction between viruses and honey bees has given
Beeologics scientists the insight to create a roadmap for developing a
rationally designed formulation that will prevent viral infection.
Beeologics' product development philosophy is based on a balance between meeting the immediate needs of the beekeeping industry, the time it takes to develop appropriate products and the availability of technology. True to our mission, the Beeologics team committed its efforts to what we strongly believe will make the most significant impact on bee health within the most reasonable time frame.
Remebee™ our first line of defense product, was chosen to be first to market in a line of RNAi based products that are designed to protect bees from infectious diseases and parasites. Remebee is Beeologics' first breakthrough development in preventing Israeli Acute Paralysis Virus (IAPV) infection, reducing the impact of Colony Collapse Disorder (CCD) caused by bee viruses, and strengthening honey bee colonies for highly effective crop pollination. Beeologics has filed for patent protection (patent pending) for the technology that covers the Remebee line of products to include not only protection from IAPV, but also protection against all other bee viruses and pathogens.
The next two products, RemebeePro™ and RemebeePlus™ will be released in the near future. The knowledge acquired in the process of developing Remebee will have an immediate accelerating impact on the products that follow. Breakthrough in scale-up technologies completes the tool-kit that enables Beeologics to make the Remebee line of products available and affordable to the beekeeper community.
